 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alimera Sciences, Inc. (NASDAQ:ALIM - Get Free Report) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 85,800 shares, a drop of...

Alimera Sciences, Inc. (NASDAQ:ALIM) Sees Significant Decline in Short Interest

Over the last three days, A.I.dvisor has detected that ALIM's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Alimera Sciences (ALIM, $3.83) Aroon Indicator entered an Uptrend on March 26, 2024.

This is a Bearish indicator signaling ALIM's price could decline from here. Traders may explore shorting the stock or put options...

Alimera Sciences (ALIM, $3.83) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 26, 2024

Alimera Sciences (ALIM, $3.82) Aroon Indicator entered an Uptrend on March 20, 2024.

This indicator may be signaling that ALIM's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Alimera Sciences (ALIM, $3.82) entered Downtrend as Momentum indicator drops below 0 level on Mar 20, 2024

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ( Alimera or the Company ), a global pharmaceutical company whose mission is to be invaluable to patients...

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE...

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Alimera Sciences price target raised by $1 at H.C. Wainwright, here's why

Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE...

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

This price move could be a signal that ALIM may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Alimera Sciences (ALIM, $3.84) price may drop as it broke higher Bollinger Band on Mar 05, 2024

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Volume (M)	56,785.00
52-Wk High	$4.38
52-Wk Low	$1.56

ALIM Alimera Sciences Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals